CAS No.: | 827022-32-2 |
---|---|
Formula: | C24h30cln7o2 |
EINECS: | 1592732-453-0 |
Type: | Organic Intermediate |
Appearance: | Powder |
Quality: | Industrial |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Product Name | Factory Supply Pharmaceutical Intermediate Raw Material Palbociclib Powder CAS 827022-32-2 Palbociclib |
Appearance | white powder |
CAS | 827022-32-2 |
Assay | 99% |
Keywords | Palbociclib;Palbociclib Powder;Palbociclib Intermediate |
Shelf Life | 24 months when properly stored |
Storage | Keep in a cool, dry, dark location |
![]() |
What is Palbociclib ? Palbociclib is a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor approved by the FDA to treat hormone receptor-positive (HR+) metastatic breast cancer. It is used in combination with letrazole as the first-line hormonal-based therapy in postmenopausal women, or with fu lvestrant in women with disease progression following hormonal therapy. Palbociclib was discovered at Warner- Lambert and developed by Pfizer after their merger. Pfizer is also studying the effectiveness of palbociclib in a variety of other cancers at various stages in the clinic. |
Palbociclib (codenamed PD-0332991) is a drug for the treatment of ER-positive and HER2-negative breast cancer developed. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Q: What's your MOQ ?
A: For the high value product, our MOQ starts from 1g and generally starts from 10gs. For other low, price product, our MOQ starts from 100g and 1kg.
Suppliers with verified business licenses